IRIX IRIDEX Corp Forecast, Technical & Fundamental Analysis
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases... Show more
IRIX is expected to report earnings to fall 33.33% to -1 cents per share on August 06
Q2'26
Est.
$-0.02
Q1'26
Beat
by $0.02
Q4'25
Beat
by $0.01
Q3'25
Missed
by $0.03
Q2'25
Beat
by $0.03
The last earnings report on May 19 showed earnings per share of -2 cents, beating the estimate of -5 cents. With 38.44K shares outstanding, the current market capitalization sits at 18.71M.
A.I. Advisor
published General Information
General Information
a manufacturer of light-based medical systems and delivery devices
A.I.dvisor tells us that IRIX and NTRA have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IRIX and NTRA's prices will move in lockstep.
IRIX in upward trend: price may jump up because it broke its lower Bollinger Band on July 13, 2026
IRIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 46 cases where IRIX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IRIX advanced for three days, in of 209 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 111 cases where IRIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for IRIX moved out of overbought territory on June 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IRIX as a result. In of 107 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for IRIX turned negative on June 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
IRIX moved below its 50-day moving average on July 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IRIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: IRIX's P/B Ratio (270.270) is very high in comparison to the industry average of (11.208). P/E Ratio (0.000) is within average values for comparable stocks, (65.302). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.948). IRIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (0.349) is also within normal values, averaging (25.206).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
